The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9835636 B1

PDF
Full Text
Expired
Date of Patent:
Dec. 05, 2017

Filed:

May. 10, 2013
Applicant:

Chang Gung University, Tao-Yuan, TW;

Inventors:

Err-Cheng Chan, Tao-Yuan, TW;

Kuei-Tien Chen, Tao-Yuan, TW;

Jau-Song Yu, Tao-Yuan, TW;

Yu-Sun Chang, Tao-Yuan, TW;

Jinn-Shiun Chen, Tao-Yuan, TW;

Assignee:

CHANG GUNG UNIVERSITY, Tao-Yuan, TW;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/53 (2006.01); G01N 33/92 (2006.01); G01N 33/574 (2006.01); C07K 14/47 (2006.01); C12N 9/14 (2006.01);
U.S. Cl.
CPC ...
G01N 33/92 (2013.01); G01N 33/57419 (2013.01); C07K 14/47 (2013.01); C12N 9/14 (2013.01);
Abstract

Embodiments relate to serological markers for detecting the colorectal cancer and applications of the serological markers. A phospholipid scramblase1 (PLSCR1), a stomatin-like protein 2 (STOML2) or a transport protein Sec61β (SEC61β) increases expression in the blood at the earlier stage of the colorectal cancer. Detecting the expression of the PLSCR1, STOML2 or SEC61β protein or an induced autoantibody of each protein in a blood sample is used to diagnose the colorectal cancer. Moreover, the serological marker improves the detection efficiency and the sensitivity in detecting the colorectal cancer and is used to predict the prognosis. The serological markers are applied in preparing a detection device or inhibiting the growth of the colorectal cancer cells.


Find Patent Forward Citations

Loading…